DELRAY BEACH, Fla., Oct. 20, 2010 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or the "Company") (Nasdaq:PSID) announced today that it has received an initial order of 15,000 iGlucose™ units from Liberator Medical Holdings, Inc. ("Liberator"). Liberator offers over 5,000 products to Medicare-eligible patient populations with chronic conditions requiring repeat-orders of maintenance supplies.
Scott R. Silverman, Chairman and CEO of PositiveID, said, "We are very pleased to announce this important distribution partner for our iGlucose product, Liberator Medical led by founder and CEO Mark Libratore. As experts in the use of a national direct-to-consumer advertising model that has fueled the growth of Liberator Medical, we believe Mr. Libratore and his team can help us rapidly grow the awareness and adoption of iGlucose."
Liberator's order is subject to PositiveID having obtained all final regulatory clearances required to sell iGlucose in the United States.
About PositiveID Corporation
PositiveID Corporation develops and markets healthcare and information management products through its RFID-based diagnostic devices and identification technologies, and its proprietary disease management tools. PositiveID operates in two main divisions: HealthID and ID Security. For more information on PositiveID, please visit .
The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717
Statements about PositiveID's future expectations, including the likelihood Liberator's founder and CEO Mark Libratore and his team can help the Company rapidly grow the awareness and adoption of iGlucose, the likelihood that the Company can obtain all final regulatory clearances required to sell iGlucose in the United States, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include the Company's ability to receive FDA clearance for and successfully commercialize its iGlucose product, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 19, 2010, and the Company's 10-Qs filed on May 6, 2010, and August 13, 2010, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT: PositiveID Corporation Allison Tomek 561-805-8000 firstname.lastname@example.org CEOcast Dan Schustack 212-732-4300 email@example.com